FyMed Expands Its Discovery and Drug Development Plans Through Innovative Strategies in Precision Medicine
10/20/15 02:21 Filed in: expansions | pharmaceutical company | biotechnology company | precision medicine | drug discovery
FyMed, Inc. today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing innovative companion diagnostic and prognostic technologies in precision medicine.
Read More...
Read More...
FyMed Announces Notice of Allowance for US Patent Covering Fy10 Technology Platform
05/15/15 09:00 Filed in: patent | drug discovery | precision medicine | anti-inflammatory | immunomodulatory | Novel | FY10
FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...
Early Release: FyMed Gets Patent for Novel Immunomodulatory Drug
Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.
Read More...
Read More...
FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B
02/16/15 08:00 Filed in: innovations | drug discovery | pharmaceutical company | cancer | FY405B | superior | colon
Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...
FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract
10/12/14 10:30 Filed in: innovations | drug discovery | pharmaceutical company | cancer | FY103B | superior | NSAID | ibuprofen | intestinal
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...
FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation
04/22/14 11:10 Filed in: innovations | drug discovery | pharmaceutical company | FY103B | superior | NSAID | ibuprofen
FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety. Read More...
FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen In the Treatment of Pain and Inflammation
07/19/13 10:30 Filed in: innovations | drug discovery | pharmaceutical company | FY101C | superior | NSAID | ibuprofen
FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic pain and inflammation. Read More...
FyMed Reinforces Its Drug Development Pipeline With Novel Strategies in Precision Medicine
10/02/12 02:16 Filed in: pharmaceutical company | biotechnology company | precision medicine | drug discovery | personalized medicine
FyMed, Inc., a pharmaceutical company utilizing proprietary methodologies in evidence-based medicine for drug discoveries recently announced plans for the strategic and operational reinforcements of their drug development pipeline through innovative approaches in precision medicine. Read More...
